This table compares various known prostate cancer therapeutics, such as finasteride, abiraterone acetate, enzalutamide, apalutamide, and darolutamide, alongside natural compounds like ecdysterone, inokosterone, and 20-hydroxyecdysone (20-HE), with binding information against DNMT1, Dicer, PD-1, and PD-L1. Here, DICER1 is linked to prostate cancer.